<DOC>
	<DOCNO>NCT00657826</DOCNO>
	<brief_summary>The initial clinical investigation title `` ATS 3f ( r ) Aortic Bioprosthesis Model 1000 Study , '' prospective , non-randomized , multi-center study design evaluate safety effectiveness obtain 800 patient year use common clinical protocol . Twenty-three ( 23 ) sit internationally United States combine enrolled 405 patient . The objective study evaluate safety effectiveness ATS 3f ( r ) Aortic Bioprosthesis Model 1000 equine pericardial prosthesis patient population undergo isolated aortic valve replacement / native aortic valve , replacement fail prosthesis without concomitant procedure . Addendum : After receive PMA approval October 2008 21mm-29mm size , IDE expand comply condition set forth approval notice . Study Protocol S2001 Rev . E continuation original protocol , enrol subject require 19mm ATS 3f ( r ) Aortic Bioprosthesis , Model 1000 describe `` A multi-center , non-randomized trial , design obtain 800 patient year . Each enrol patient follow minimum one year annually thereafter size 19mm product approval study cessation . Preoperative , discharge 30 day ( ever come last ) , 3-6 month , annual follow-up data require .</brief_summary>
	<brief_title>ATS 3f ( r ) Aortic Bioprosthesis Model 1000 , 19mm</brief_title>
	<detailed_description>The patient ATS Medical , Inc. , ATS 3f ( r ) Aortic Bioprosthesis Model 1000 intend patient whose prognosis without surgery replacement diseased natural valve previous implant prosthetic valve unacceptably poor term survival , quality life , , opinion attend physician . For special subset patient , number widely accept prosthetic heart valve use .</detailed_description>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>This patient require isolated aortic valve replacement without concomitant procedure coronary artery bypass another valve reconstruction . ( The three remain valve must native tissue ) . This patient sufficiently ill warrant replacement his/her diseased natural prosthetic valve , base standard cardiovascular diagnostic workups . This patient satisfactory condition , base physical exam investigator 's experience , average well operative risk , ( i.e. , likely survive one year postoperatively ) . This patient geographically stable willing return implant center followup visit . This patient adequately informed consent his/her participation clinical study , require him/her , order comply protocol . This patient twenty ( 20 ) less twenty year age . This patient noncardiac major progressive disease , investigator 's experience produce unacceptable increase risk patient , result life expectancy le 12 month . This patient intravenous drug and/or alcohol abuser . This female patient pregnant ( urine HCG test result positive ) , lactate . This patient present active endocarditis . This patient present congenital bicuspid aortic anatomy . This patient previously implant prosthetic valve replace study valve . This patient require mitral , tricuspid pulmonic valve replacement . This patient participate concomitant research study investigational product . This patient agree return implant center require number followup visit geographically unavailable followup .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Diseased Heart Valve , Replacement</keyword>
</DOC>